Comprehensive diagnosis and surgical management of ovarian cancer, including staging, cytoreductive surgery and multidisciplinary treatment planning.
Evaluation and treatment of cervical cancer using appropriate surgical, oncological and multidisciplinary approaches based on the stage of disease.
Diagnosis and surgical management of uterine or endometrial cancer, including minimally invasive surgery and staging procedures where appropriate.
Specialised surgical care for vulvar cancer, including appropriate staging and sentinel lymph node evaluation in selected patients.
Personalised multidisciplinary treatment planning for rare cancers affecting the vagina.
Specialised evaluation and surgical management of rare malignant tumours arising from the muscle or connective tissue of the uterus.
Diagnosis, monitoring and multidisciplinary management of pregnancy-related trophoblastic tumours.
Advanced robotic-assisted surgery may be used for selected gynecologic cancers to support precision and minimally invasive treatment.
Laparoscopic and other minimally invasive surgical techniques may be used for selected gynecologic cancers to reduce surgical trauma and support recovery.
A specialised technique used to identify the first lymph nodes where cancer may spread, helping with accurate staging while potentially reducing unnecessary lymph-node removal.
Extensive surgical removal of visible tumour burden, particularly in selected patients with ovarian cancer, to support optimal cancer treatment.
Selected young patients with early-stage gynecologic cancers may be considered for fertility-preserving surgical approaches when medically appropriate.
Detailed examination of the cervix to assess abnormal screening results and identify pre-cancerous cervical changes.
Evaluation and treatment of cervical pre-cancer to help prevent progression to invasive cervical cancer.
Preventive counselling, HPV vaccination and cervical screening strategies aimed at reducing the risk of cervical cancer.
Assessment of inherited cancer syndromes such as BRCA- and Lynch-associated cancer risk, with referral for genetic counselling where appropriate.
Long-term follow-up focused on recovery, quality of life, treatment-related effects, recurrence monitoring and overall wellbeing after cancer treatment.